Ascendis Presents TransCon PTH Data at the American Thyroid Association Annual Meeting

02.10.2023 - – At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with ... Seite 1

Related Keywords

Denmark ,Japan ,United States ,Copenhagen ,Køavn ,American ,Ascendis Pharma ,Aimee Shu ,European Union ,American Thyroid Association ,Endocrinology Medical Sciences At Ascendis Pharma ,Clinical Development ,Vice President ,Endocrinology Medical Sciences ,Ascendis Pharma Chart ,Scendis Pharma Kurs ,Scendis Pharma Aktie ,